European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc.
Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney damage, and kidney failure, which may lead to death. PH has three main types, PH1, PH2 and PH3, and is estimated to affect approximately 0.1 in 10,000 people, which is roughly 5,000 people in the European Union (EU).1 The most severe and most common type among genetically characterized patients is PH1. These patients typically develop recurrent kidney stones, progressive renal damage, chronic kidney disease and end stage renal disease at a median age of 24 years of age.2 There are no EU approved therapies for PH, and the most severe patients may be treated with liver and/or kidney transplant.
ALLN-177 is a first-in-class therapeutic being developed to treat patients with severe hyperoxaluria using an oral, non-absorbed enzyme that works in the gastrointestinal (GI) tract, where it is designed to degrade both dietary and endogenously produced oxalate that is secreted into the GI tract. GI elimination of oxalate has potential to help alleviate the chronic systemic oxalate burden on PH patients.
“Primary Hyperoxaluria is a debilitating disease, which starts at a young age and leads to renal failure in young adulthood. It’s imperative that we have better therapeutic options to treat this disease,” said Eduardo Salido, M.D., Ph.D., Professor of Pathology at Universidad de La Laguna, Tenerife, Spain. Dr. Salido recently hosted the 12th International PH Workshop for Professionals, Patients and Families organized by the Oxalosis and Hyperoxaluria Foundation and is on the steering committee of Oxal Europe, the European Hyperoxaluria Consortium. Dr. Salido also co-authored a previous publication that demonstrated that oxalate decarboxylase significantly reduced urinary oxalate levels in a pre-clinical disease model of PH. This study was one of multiple animal studies including a rodent disease model and a porcine model of hyperoxaluria with hyperoxalemia that supported the ALLN-177 orphan drug designation application to the European Medicines Agency (EMA).
“This regulatory designation from the European Commission represents an expansion of our previous efforts in United States,” said Louis Brenner, M.D., President and Chief Operating Officer of Allena Pharmaceuticals. “We are excited to develop ALLN-177 to address the oxalate disease burden for PH patients in both the US and EU, where there are no US Food and Drug Administration or European Commission approved therapies for this unmet medical need.”
About Hyperoxaluria and ALLN-177
Hyperoxaluria is a metabolic disorder resulting from high oxalate levels in the urine due to either overproduction of oxalate by the liver due to a genetic defect (primary) or from hyper-absorption of oxalate from the diet (secondary). Secondary hyperoxaluria can be due to an unknown cause (idiopathic) or as a result of underlying GI disorders (enteric). Kidney stones are typically the first sign of hyperoxaluria, are often painful, and may require interventional procedures. Severe hyperoxaluria in settings of enteric and primary hyperoxaluria may also lead to kidney damage (nephrocalcinosis), chronic kidney disease and end-stage renal disease, which may lead to death.
ALLN-177 is an orally-administered, recombinant oxalate-degrading enzyme in development for the treatment of severe hyperoxaluria. ALLN-177 is being developed to target oxalate in the GI tract in an effort to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as reduce long-term kidney complications. ALLN-177 is an investigational product, and its safety and efficacy have not been evaluated by the EMA or any other health authority.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases. Allena is completing a Phase 2 program in secondary hyperoxaluria. The company’s technological approach enables the design and development of oral enzyme therapies that are designed to remain in the gastrointestinal (GI) tract, where the enzyme exerts its therapeutic effect by degrading certain nephrotoxic metabolites, without being absorbed into the bloodstream. Led by a proven management team with deep expertise in enzyme therapeutic design, development, and commercialization, Allena is committed to bringing breakthrough new treatments to patients with unmet medical needs. Based in Newton, MA, the company is supported by a top-tier investor syndicate including Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners, HBM Partners, Pharmstandard International S.A., Partner Fund Management, Fidelity Management & Research Company, and other investors. For more information, please visit www.allenapharma.com (http://www.allenapharma.com).
1. The European registry of orphan diseases (Orphanet 2013).
2. Cochat P., Rumsby G. Primary Hyperoxaluria. New England Journal of Medicine. 2013;369(7):649-658.
Allena Pharmaceuticals, Inc.
Janet Giroux, 617-467-4577
Manager of Corporate Operations
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Nearly 1 Billion People Worldwide Have Sleep Apnea, International Sleep Experts Estimate21.5.2018 18:15 | Pressemelding
A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater than previous estimates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005096/en/ Woman wearing CPAP, the gold standard treatment for sleep apnea (Photo: Business Wire) The study “Global Prevalence of Obstructive Sleep Apnea (OSA)” was conducted by an international panel of leading researchers seeking to provide a clear scope of the impact of the chronic sleep-disordered breathing condition. The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. By analyzing technology improvements in detecting OSA and underreported statistics from other areas of the world, this latest study depicts an impacte
Pietro Rosa TBM Signs Long-Term Agreement with Pratt & Whitney21.5.2018 15:13 | Pressemelding
Pietro Rosa TBM (Turbine Blade Manufacturing) today announced that it has signed a 10-year, long-term agreement (LTA) with Pratt & Whitney, a division of United Technologies Corp., to supply airfoil products for both commercial and military engines. The LTA, which may extend to the entire Pietro Rosa TBM Group in Europe and the United States, will support Pratt & Whitney’s F135, PW2000 and the Geared Turbofan™ (GTF) family of engines. This agreement represents a significant step in the collaboration between the two companies, enabling the Pietro Rosa TBM Group to utilize its advanced engineering capabilities and the vertical integration of hot forming, machining and surface finishing technologies. “We’re pleased to sign this agreement with Pietro Rosa,” said Art Erikson, executive director of Strategic Sourcing, Pratt & Whitney. “We have tremendous growth ahead, and suppliers like Pietro Rosa that sign up to our contractual governance, commitment to cost competitiveness and continuous
NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00 | Pressemelding
NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip
Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00 | Pressemelding
Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior
Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27 | Pressemelding
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea
Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00 | Pressemelding
Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba